Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Significant publications on infectious diseases pharmacotherapy in 2013.

Hunter AS, Guervil DJ, Perez KK, Schilling AN, Verheyden CN, Vuong NN, Xu R; Houston Infectious Diseases Network.

Am J Health Syst Pharm. 2014 Nov 15;71(22):1974-88. doi: 10.2146/ajhp140148.

PMID:
25349243
2.

Significant publications on infectious diseases pharmacotherapy in 2012.

Bowers DR, Hunter AS, Jacobs DM, Kuper KM, Musick WL, Perez KK, Shah DN, Schilling AN.

Am J Health Syst Pharm. 2013 Nov 1;70(21):1930-40. doi: 10.2146/ajhp130129.

PMID:
24128968
3.

Significant publications on infectious diseases pharmacotherapy in 2011.

Tran TT, Beyda ND, Biehle LR, Cottreau JM, Echevarria K, Musick WL, Perez KK, Schilling AN; Houston Infectious Diseases Network.

Am J Health Syst Pharm. 2012 Oct 1;69(19):1671-81.

PMID:
22997121
4.

In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing.

Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE.

Diagn Microbiol Infect Dis. 2009 Aug;64(4):427-33. doi: 10.1016/j.diagmicrobio.2009.03.031.

PMID:
19631096
5.

Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia.

Tam VH, Chang KT, Schilling AN, LaRocco MT, Genty LO, Garey KW.

Diagn Microbiol Infect Dis. 2009 Mar;63(3):279-85. doi: 10.1016/j.diagmicrobio.2008.11.007. Epub 2009 Jan 8.

PMID:
19135330
6.

Mathematical modelling response of Pseudomonas aeruginosa to meropenem.

Tam VH, Schilling AN, Poole K, Nikolaou M.

J Antimicrob Chemother. 2007 Dec;60(6):1302-9. Epub 2007 Oct 3.

PMID:
17913722
7.

Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.

Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, Garey KW.

Diagn Microbiol Infect Dis. 2007 Jul;58(3):309-14.

PMID:
17617302
8.

Modeling of microbial population responses to time-periodic concentrations of antimicrobial agents.

Nikolaou M, Schilling AN, Vo G, Chang KT, Tam VH.

Ann Biomed Eng. 2007 Aug;35(8):1458-70. Epub 2007 Apr 13.

PMID:
17431788
9.

Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa.

Tam VH, Schilling AN, LaRocco MT, Gentry LO, Lolans K, Quinn JP, Garey KW.

Clin Microbiol Infect. 2007 Apr;13(4):413-8.

10.

Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.

Tam VH, Kabbara S, Vo G, Schilling AN, Coyle EA.

Antimicrob Agents Chemother. 2006 Aug;50(8):2626-31.

11.

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA.

Antimicrob Agents Chemother. 2005 Dec;49(12):4920-7.

12.

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE.

Antimicrob Agents Chemother. 2005 Sep;49(9):3624-30.

13.

Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa.

Tam VH, Schilling AN, Melnick DA, Coyle EA.

Diagn Microbiol Infect Dis. 2005 Jun;52(2):145-51.

PMID:
15964503
14.

Modelling time-kill studies to discern the pharmacodynamics of meropenem.

Tam VH, Schilling AN, Nikolaou M.

J Antimicrob Chemother. 2005 May;55(5):699-706. Epub 2005 Mar 16.

PMID:
15772138
15.

Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.

Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN.

Antimicrob Agents Chemother. 2004 Nov;48(11):4315-21.

Supplemental Content

Loading ...
Support Center